Oxford Cannabinoid Technologies Holdings Plc, the holding company of Oxford Cannabinoid Technologies Ltd (OCT), debuted on the Main Market of the LSEG (London Stock Exchange Group) on 21st May, 2021. OCT is a UK-based pharmaceutical company currently developing AAT-730 (OCT461201), a CB2 receptor agonist licensed from AskAt Inc.
According to OCT’s prospectus, the company will allocate approximately ₤3.5 million from the offering proceeds to the development of AAT-730. Actually, AAT-730 is one of the OCT’s most advanced program and their first priority will be completing the preclinical development and CMC production of AAT-730, followed by entry into Phase 1 clinical trials in the Third Quarter of 2022.
Please refer the following links for details.
